PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, completed the development of a blood test that determines the mRNA expression levels of the A3 adenosine receptor. The latter is a G protein cell surface receptor, highly expressed in inflammatory and cancer cells and has low expression in normal cells. The Company drugs target with high affinity and selectivity this cell surface receptor.
